NCT05618782View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

518

Participants

Timeline

Start Date

October 19, 2022

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions
PainOsteo Arthritis KneeKnee OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases
Interventions
DRUG

LEVI-04

LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR), for the treatment of chronic pain.

OTHER

Placebo

Saline vehicle

Trial Locations (13)

Unknown

CCR Brno, s.r.o, Brno

CCR Czech a.s, Pardubice

CCR Prague, s.r.o, Prague

Sanos Clinic Nordjylland, Gandrup

Sanos Clinic Herlev, Herlev

Sanos Clinic Syddanmark, Vejle

Hong Kong Center for Clinical Research, Hong Kong

PMSI Cardiology Institute/RTL SM SRL Consultative ward, Chisinau

"PMSI Clinical Republican Hospital Timofei Mosneaga", Chisinau

NZOZ Bif-Med. s.c., Bytom

Somed CR, Lodz

Medyczne Centrum Hetmańska, Poznan

Somed CR, Warsaw

Sponsors

Lead Sponsor

Levicept
All Listed Sponsors
collaborator

Nordic Bioscience Clinical Development (NBCD)

UNKNOWN

lead

Levicept

INDUSTRY

NCT05618782 - Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter